Complete IT Services and Pharma Export Champions Analysis When Suresh invested ₹10 lakh equally across TCS and a domestic IT company with “attractive” P/E 18x (vs. TCS at 28x), he
Tag: Pharma Investing
Patents, R&D, pipeline ROI, generic vs specialty
